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Abstract 
Purpose: To study the effect of Guizhi-jia-houpu-xingzi (GHX) on ovalbumin-induced allergic asthma in 
rats.  
Methods: An animal model of allergic asthma (AA) in rats was established by intraperitoneal injection 
(ip) of ovalbumin (OVA). Thereafter, GHX (375 mg/kg) was administered orally for 7 days. Pulmonary 
function, inflammatory cells, immunoglobulin E (Ig) E, interleukin-4 (IL)-4 and interferon-γ (IFN)-γ in 
serum and bronchoalveolar lavage fluids (BALF) were determined. Furthermore, mRNA expressions of 
Toll-like receptors (TLRs) signal pathway was determined using real time polymerase chain reaction 
PCR (q-RT-PCR).  
Results: GHX (375 mg/kg) significantly decreased respiratory rate (p < 0.01) and Penh value (p < 0.05) 
when compared with AA rats. The inflammatory cells (p < 0.01) and levels of IL-4 (p < 0.01) and IgE (p 
< 0.01) were significantly decreased by GHX treatment when compared with AA rats; whereas IFN-γ (p 
< 0.05) was significantly increased. Furthermore, GHX significantly decreased the mRNA expressions of 
GATA binding protein (GATA)-3 (p < 0.01), TRL-2 (p < 0.01), TRL-4 (p < 0.01), myeloid differentiation 
factor 88 (MyD88) (p < 0.01), TNF receptor associated factor 6 (TRAF6) (p < 0.01) and β-arrestin (p < 
0.01) in lung tissues, relative to AA rats. However, GHX treatment led to significant up-regulation of 
mRNA expression of T-bet (p < 0.01). 
Conclusion: These results demonstrate that GHX possesses a potential for treating allergic asthma via 
regulation of Toll-like receptor (TLR) signal pathway. They also provide a scientific basis for the 
probable use of GHX in clinical treatment of allergic diseases in future.  
 
Keywords: Guizhi-jia-houpu-xingzi decoction, Ovalbumin, Allergic asthma, Toll-like receptor 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Current epidemiologic studies have revealed that 
the prevalence and incidence of allergic diseases 
(especially allergic asthma) have increased 
sharply world-wide [1,2]. Allergic asthma is a 
complex chronic airway inflammatory reaction 
mediated by mastocytes, eosinophils and T-
lymphocyts [3,4]. Recent reports showed that 
morbidity from allergic asthma is approximately 
18 % in Western counties, and that there are 
about 300 million allergic asthma patients in the 
world, while over 180 thousand patients die 
yearly from the disease [5,6]. Therefore, allergic 
asthma is a serious threat to public health. 
 
Currently available drugs for treating allergic 
asthma are mainly bronchodilators, anti-
inflammatory drugs, leukotriene receptor 
antagonists and immune-modulators, such as 
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theophylines, immunoglobulin (Ig) E and 
glucocorticoids [7,8]. However, these drugs just 
alleviate only the symptoms of allergic asthma 
without providing radical cure [9]. In addition, 
longtime use of these drugs might result in some 
serious side-effects, such as gastrointestinal 
discomfort, drug dependency, and blood capillary 
injury [8,10]. Thus, it has become necessary to 
find some new sources of reliable drugs of low 
toxicity for curing allergic asthma. 
 
Guizhi-jia-houpu-xingzi decoction (GHX) is a 
popular traditional Chinese formula used which 
produces good therapeutic effects on allergic 
asthma in clinics [11]. It has been reported that 
GHX down-regulated TNF-α in bronchoalveolar 
lavage fluids (BALF) of experimental asthma 
guinea pig, indicating that GHX may have 
potential benefits for allergic asthma patients 
[12]. However, so far, there are no systemic 
animal studies and its mechanism of action 
extensively limits the clinical application of GHX 
in the treatment of allergic asthma or other 
allergic diseases. In the present study, an 
experimental allergic asthma rat animal model 
was established induced by induction with 
ovalbumin (OVA). Based on the animal model, 
the therapeutic effects of GHX were evaluated 





Chemicals and reagents. 
 
Ovalbumin (OVA) was purchased from Sigma-
Aldrich Co. (Shanghai, China). Aminophylline 
(ANP) was purchased from Southwest Pharm. 
Ltd. (Chongqing, China). Trizol reagents were 
products of Invitrogen Co. (Carlsbad, CA, USA). 
Rat Elisa kits for secretory immunoglobulin A (sIg 
A), immunoglobulin E (IgE), interleukin-4 (IL-4) 
and interferon- γ (IFN-γ) were products of 
Neobioscience Co. (Shenzhen, China). HiScript 
1st Strand cDNA Synthesis kits and SYBR Green 
Master Mix were products of Vazyme Biotech. 
(Nanjing, China). Hematoxylin and eosin (H & E) 
was purchased from the Baso Biotech. (Zhuhai, 
China). All primers used in the study were 
designed by Primer-Express v3.0 and 
synthesized by Sangon Biotech. (Shanghai, 




Male Sprague-Dawley (SD) rats (3 - 4 weeks old, 
200 ± 20 g) were purchased from the Dashuo 
Laboratory Animal Co. Ltd (Chengdu, China) and 
were kept in a temperature (22 ± 2 °C) and 
humidity (40 – 60 %) controlled room with food 
and water provided ad libitum. All the animal 
experimental protocols were according to the 
International Principles of Laboratory Animal 
Care [13] and approved by the Ethics Committee 
for Laboratory Animal Experimentation of 
Chengdu University of Traditional Chinese 
Medicine (approval no. 2014KL-061). 
 
Preparation of GHX extracts 
 
All the crude TCMs in GHX were decocted with 
pure water. The TCMs were Cinnamomi ramulus 
(9 g), Magnoliae officinalis cortex (6 g), 
Armeniacae semen amarum (6 g), Paeoniae 
radix alba (9 g), Glycyrrhizae radix rhizoma (6 g), 
Zingiberis rhizoma recens (9 g) and Jujubae 
fructus (15g).  
 
 
      Table 1: Primers used  
 
Gene  Sequence 
















 Reverse 5’-GCCGATAGTCTGTCTGTTCT-3’ 
 




 Reverse 5’-TGCACCTTGAGGCATCTCTG-3’ 
β-Actin Forward 5’-AGGGAAATCGTGCGTGACAT-3’ Reverse 5’-GAACCGCTCATTGCCGATAG-3’ 
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The TCMs were purchased from Beijing 
Tongrentang TCM Chain Drug Store (Chengdu, 
China). They were authenticated by Professor 
Min Li (Department of Pharmacognosy, College 
of Pharmacy, Chengdu University of TCM, 
Chengdu, China). After decocting 3 times (each 
for 1 h), the total extracts were filtered and 
subsequently dried in vacuum at 55 °C to obtain 
the GHX extract (yield was approximately 10 %). 
The dose of GHX used (375 mg/kg) in this 
research was estimated from its clinical dose.  
 
Experimental protocols and animal model 
preparation  
 
A total of 40 rats were randomly divided into 4 
groups (n =10): 1) normal group, 2) model group 
(control group), 3) positive treatment group 
[treated with aminophylline (ANP)], 4) GHX 
treatment group (375 mg/kg). Except for the 
normal rats, all animals in control and positive 
groups were treated with OVA to induce allergic 
asthma (AA) rats according to previously 
described methods with minor modifications [4]. 
Rats were immunized via intraperitoneal injection 
(ip) of 1 mL OVA- aluminum hydroxide mixture (1 
mg OVA and 200 mg aluminum hydroxide were 
dissolved in 1 mL saline) on days 0 and 7. 
Thereafter, the rats were activated with 1 % 
OVA-saline solution by aerosol inhalation in a 
glass box (10 cm × 10 cm × 20 cm) from 14 to 21 
days (30 min/day). Rats in the normal group 
were subjected to the same procedure, but with 
saline in place of OVA and aluminum hydroxide 
mixture. In the positive and GHX treatment rats, 
ANP (300 mg/kg) and GHX (375 mg/kg) were 
administered orally from 14th to 21st day. On day 
21, pulmonary functions were determined, and 
after that, the rats were sacrificed under 
anesthesia using pentobarbital sodium (45 
mg/kg, ip) after collection of blood samples and 
bronchoalveolar lavage fluids (BALF). The lung 
tissues were excised for the following 
biochemical assays [14,15]. 
 
Determination of pulmonary functions  
 
Pulmonary functions (respiratory rate and airway 
hyperreactivit) were determined using a Buxco 
Animal Pulmonary Function analysis system 
(FinePointe™ NAM, Data Sciences International 
Inc, St. Paul, MN, USA).  
 
Blood cell count 
 
Blood smears were prepared and fixed with 
formalin. Wright-Giemsa staining was performed, 
and subsequently the cell counts was carried out 
under an optical microscope (Olympus 2H12003, 
Tokyo, Japan).  
Assay of sIgA, IgE, IL-4 and IFN-γ by ELISA 
 
The levels of sIgA and IgE in BALF and levels of 
IL-4 and IFN-γ in serum were determined by 
commercial ELISA kits according to the 
manufactures’ instructions. Absorbance was read 
at 450 nm in a micro-plate reader (Thermo 
Mulliskan Ascant 413MBY042078, Waltham, MA, 
USA).  
 
Real-time PCR (qRT-PCR) assay 
 
Lung tissues obtained from each rat were 
separately homogenized, and total RNA 
extracted with Trizol reagent. Subsequently, the 
total RNA was used for synthesis of cDNA for 
GATA-3, T-bet, TRL-2, TRL-4, MyD88, β-arrestin 
and β-actin with reverse transcription by using 
qRT-PCR (CFX96TM Real-Time System, Bio-
Rad, Hercules, CA, USA). The mRNA primers 
used in the real-time PCR experiments are 
shown in Table 1. Reverse transcription was 
performed according to the manufacturer’s 
instructions on the commercial kits for the 




Data are expressed as mean ± standard 
deviation (SD). Statistically significant differences 
were analyzed using two-tailed Student's t-test 
using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). 





Pulmonary function  
 
Compared with normal rats, the respiratory rate 
(p < 0.01) and penh value (p < 0.01) of the 
allergic asthma model rats were significantly 
increased. However, similar to positive drug 
treatment, GHX (375 mg/kg) significantly 
reversed the increases in respiratory rate (p < 
0.01) and Penh value (p < 0.05) when compared 
with the control rats (Figure 1). 
 
Blood cell count 
 
Eosinophils, neutrophils, lymphocytes and 
monocytes are significantly increased in the 
allergic asthma control rats when compared to 
normal rats (p < 0.01, Table 1). In contrast, the 
positive treatment reversed the increases in 
these inflammatory cells (p < 0.01, p < 0.01, p < 
0.05 and p < 0.01, respectively). Similar to the 
positive drug, GHX (375 mg/kg) treatment also 
resulted in significant decreases in all the four  
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         Table 2: Blood cell count (×106/L) 
 







Normal 2.66 ± 1.20 22.50 ± 5.50 37.00 ± 5.00 2.00 ± 0.36 
Control 27.75 ± 2.19## 41.85 ± 1.92## 68.50 ± 3.52## 5.33 ± 0.88## 
Positive 3.28 ± 0.47** 29.00 ± 1.15** 55.00 ± 2.30* 2.88 ± 0.26** 
375 mg/kg 2.37 ± 0.37** 23.00 ± 3.60** 30.33 ± 3.77** 2.66 ± 0.88** 
Aminophylline (300 mg/kg) was used as positive drug. Data presented as mean ± SD (n = 10); *p < 0.05, **p < 
0.01, vs. control rats; ##p < 0.01, vs. normal rats 
 
 
Figure 1: Respiratory rate (A) and Penh value (B). Aminophylline (300 mg/kg) was used as positive drug. Data 
are presented as mean ± SD (n = 10); *p < 0.05, **p < 0.01, vs. control rats; ##p < 0.01, vs. normal rats 
  
   
     Group       Group       Group  
Figure 2: ELISA assays for IgE in serum (A), and IL-4 (B) and IFN-γ (C) in BALF. Aminophylline (300 mg/kg) 
was used as the positive drug. Data are presented as mean ± SD (n = 10); *p < 0.05, **p < 0.01, vs. control rats; 
##p < 0.01, vs. normal rats 
 
blood cell counts relative to corresponding values 
for control rats (p < 0.01). 
 
Levels of IgE in serum and IL-4 and IFN-γ in 
BALF  
 
As shown in Figure 2A, serum IgE was sharply 
increased (p < 0.01) when compared to normal 
rats. After treatment with positive drugs (p < 
0.01) and GHX (375 mg/kg), level of IgE was 
significantly decreased (p < 0.01) when 
compared to that of control rats. After induction 
with OVA, the IL-4 levels (p < 0.01, Figure 2B) of 
control rats were significantly increased whereas 
IFN-γ (p < 0.01, Figure 2C) was significantly 
decreased. For the positive treated rats, the IL-4 
(p < 0.01, Figure 2B) was significantly decreased 
and the IFN-γ (p < 0.01, Figure 2C) was 
significantly increased compared with the control 
rats. Importantly, GHX treatment showed similar 
results to the positive drugs, and IL-4 levels in 
BALF were significantly decreased by treatment 
with GHX (375 mg/kg) (p < 0.01, Figure 2B) 
whereas the IFN-γ levels were significantly 
increased by GHX at the dose of 375 mg/kg (p < 
0.05, Figure 2C). 
 
mRNA expressions of GATA-3, TRL-2, TRL-4, 
MyD88, TRAF6 and β-arrestin  
 
As shown in Figure 3, the mRNA expressions of 
GATA-3 (p < 0.01),  TRL-2 (p < 0.01), TRL-4 (p < 
0.01), MyD88 (p < 0.01), TRAF6 (p < 0.01)and β-
arrestin (p < 0.01) were significantly up-regulated 
in the lung tissues whereas that of T-bet (p < 
0.01)was significantly down-regulated when 
compared with normal rats. Interestingly, the 
positive treatment and GHX (375 mg/kg) brought 
about significant decreases in the mRNA 
expressions of GATA-3 (p< 0.01), TRL-2 (p < 
0.01), TRL-4 (p < 0.01), MyD88 (p < 0.01), 
TRAF6 (p < 0.01) and β-arrestin (p < 0.01) in 
A B 
A B C 
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Figure 3: mRNA expressions of (a) GATA-3, T-bet, TLR-2 and TLR-4 and (b) MyD88, TRAF6 and β-arrestin. 
Aminophylline (300 mg/kg) was used as the positive drugs. Data presented as Mean ± SD (n = 10); **p < 0.01, 
vs. control rats; ##p < 0.01, vs. normal rats  
 
lung tissues, when compared with control rats. 
However, mRNA expression of T-bet was up-
regulated by treatment with GHX at the dose of 




The establishment of a suitable animal model is 
the first and most crucial step in investigating the 
therapeutic effects of candidate drugs [16]. In the 
present investigation, an allergic asthma rat 
animal model was successfully prepared by 
induction with OVA. The results showed that the 
model rats manifested obvious features of 
allergic asthma, which were reflected in the 
results of pulmonary functions and inflammatory 
blood cell counts. The results also demonstrated 
that GHX has potential therapeutic effect against 
OVA-induced allergic asthma based on the rat 
model.  
 
IgE is usually expressed in allergic asthma 
patients, due probably to their high mucosal 
immune responses [17,18]. In the present 
research, GHX significantly decreased the serum 
levels of IgE in the asthmatic rats. In allergic 
asthma patients, infiltrated inflammatory cells 
over-release IL-4, which aggravates airway 
inflammatory reactions. In addition, IFN-γ/IL-4 
ratio is a reflection of the proportion of Th1 and 
Th2. Increases in IFN-γ are beneficial to asthma 
patients. The present results show that GHX 
decreased the level of IL-4 and increased the 
level of IFN-γ in BALF [19-21]. Just like IFN-γ/IL-
4 ratio, T-bet/GATA-3 ratio can also be 
considered a measure of Th1/Th2 cytokine 
profiles. Studies have shown that allergic asthma 
results from lymphocyte proliferation of allergen-
specific type 2 T-helper (Th2) with over-release 
of Th2 cytokines such as IL-4, IL-5, IL-13 and IL-
25 [19,22]. Thus, increases in T-bet/GATA-3 ratio 
would be beneficial for treating allergic asthma. 
Toll-like receptors (TLRs) are membrane-located 
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pattern recognition receptors closely related to 
immunocompetence [23,24]. TLRs can recognize 
specific conserved molecular components of 
microorganisms and then transfer the signals into 
the cell, leading to the activation of NF-κB 
[25,26].  
 
The typical pathological changes in asthma are 
airway inflammatory reactions and airway 
remodeling. TLRs play important roles in the 
development of airway inflammatory reactions, 
and activation of the MyD88- IRAK-TRAF6-IKK-
NF-κB signal pathway [27]. In addition, TLRs 
promote not only the maturity and differentiation 
of immune cells but also the conversion of CD4+ 
T cells into T-regulatory cells (Tr cells). Thus, 
TLRs-NF-κB signal pathway also 
regulatesTh1/Th2 ratio via Tr cells [28]. It has 
been reported that TLR-2 and TLR-4 are closely 
related to the re-organizations of peptidoglycan 
and lipopolysaccharides (LPS), respectively. 
 
The β-arrestin influences the functions of T cells 
in several ways, and is up-regulated in allergic 
asthma patients [29]. The present research 
shows that the expressions of TRL-2, TRL-4, 
MyD88, TRAF6 and β-arrestin mRNAs were 
significantly up-regulated in lung tissues of the 
model rats. Interestingly, the GHX treatment 
significantly decreased the expressions of 




The findings of this study demonstrate that GHX 
possesses potentials for application in the 
treatment of allergic asthma, most likely v 
regulation of TLRs signal pathway in rats. 
However, additional investigations are required 
to determine the suitability of GHX in the clinical 






The authors are grateful for the financial support 
received from National Natural Science 
Foundation of China (no. 81303085) and 
Foundation of Science & Technology Department 
of Sichuan Province (no. 2013JY0067). 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them.  
 
Open Access  
 
This is an Open Access article that uses a fund-
ing model which does not charge readers or their 
institutions for access and distributed under the 
terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/ 
4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 




1. Julia V, Macia L, Dombrowicz D. The impact of diet on 
asthma and allergic diseases. Nat Rev Immunol 2015; 
15: 308-322.  
2. Zhu J, Song J, Liu Z, Han J, Luo H, Liu Y, Jia Z, Dong Y, 
Zhang W, Jiang F, et al. Association between allergic 
conditions and risk of prostate cancer: A Prisma-
Compliant Systematic Review and Meta-Analysis. Sci 
Rep 2016; 6: 35682.  
3. Yacoub MR, Colombo G, Marcucci F, Caminati M, Sensi 
L, Di Cara G, Frati F, Incorvaia C. Effects of sublingual 
immunotherapy on allergic inflammation: an update. 
Inflamm Allergy Drug Targets 2012; 11: 285-291. 
4. Lee MY, Shin IS, Jeon WY, Lim HS, Kim JH, Ha H. 
Pinellia ternata Breitenbach attenuates ovalbumin-
induced allergic airway inflammation and mucus 
secretion in a murine model of asthma. 
Immunopharmacol Immunotoxicol 2013; 35: 410-418. 
5. Masoli M, Fabian D, Holt S, Beasley R. The global 
burden of asthma: Execurive summary of the GINA 
Dissemination Committee report. Allergy 2004; 59: 469-
478. 
6. Liu Z, Zhang XH, Callejas-Díaz B, Mullol J. MicroRNA in 
United Airway Diseases. Int J Mol Sci 2016; 17: 716. 
7. Santus P, Radovanovic D. Prostaglandin D2 receptor 
antagonists in early development as potential 
therapeutic options for asthma. Expert Opin Investig 
Drugs 2016; 25: 1083-1092. 
8. Li HJ, Kang SL, Li L. The progress of anti-asthma drugs. 
Chin J Pharmacoepidemiol 2005; 14: 272-275. 
9. Strachan DP. Family size, infection and atopy: the first 
decade of the "hygiene hypothesis". Thorax 2000; 55: 
2–10 
10. Chellaih P, Sivadas G, Chintu S, Vaishnavi Vedam VK, 
Arunachalam R, Sarsu M. Effect of anti-asthmatic drugs 
on dental health: A comparative study. J Pharm 
Bioallied Sci 2016; 8: S77-S80. 
11. Liu JC. Research of Guizhijiahoupu decoction jiajian on 
78 clinical samples of allergic asthma. Asia Pacific Trad 
Med 2015; 11: 133-134. 
Zheng et al 
Trop J Pharm Res, May 2017; 16(5): 1179  
 
12. Zhang YZ, Nie HM, Zhang N, He W, Yu ST, Hu Y. Effects 
of Guizhijiahoupuxingzi tang jiawe on the change of 
TNF-α, ET-1 in the cobaya of allergic asthma. J Beijing 
Univ Tradit Chin Med 2000; 23: 23-24. 
13. U.S. Office of Science and Technology Policy. Laboratory 
animal welfare, U.S. government principles for the 
utilization and care of vertebrate animals used in testing, 
research and training; notice. Fed Regist 1985; 50: 
20864-20865. 
14. Jang TY, Jung AY, Kim YH. Hormetic effect of chronic 
hypergravity in a mouse model of allergic asthma and 
rhinitis. Sci Rep 2016; 6: 27260.  
15. Shin D, Park SH, Choi YJ, Kim YH, Antika LD, Habibah 
NU, Kang MK, Kang YH. Dietary Compound kaempferol 
inhibits airway thickening induced by allergic reaction in 
a bovine serum albumin-induced model of asthma. Int J 
Mol Sci 2015; 16: 29980-29995.  
16. Xu L. Animal models of human diseases. Zoological 
Research 2011; 32: 1-3. 
17. Mantis NJ1, Rol N, Corthésy B. Secretory IgA's complex 
roles in immunity and mucosal homeostasis in the gut. 
Mucosal Immunol 2011; 4: 603-611.  
18. Peng W, Ming QL, Han P, Zhang QY, Jiang YP, Zheng 
CJ, Han T, Qin LP. Anti-allergic rhinitis effect of 
caffeoylxanthiazonoside isolated from fruits of Xanthium 
strumarium L. in rodent animals. Phytomedicine 2014; 
21: 824-829.  
19. Lee MY, Shin IS, Jeon WY, Lim HS, Kim JH, Ha H. 
Pinellia ternata Breitenbach attenuates ovalbumin-
induced allergic airway inflammation and mucus 
secretion in a murine model of asthma. 
Immunopharmacol Immunotoxicol 2013; 35: 410-418.  
20. Swain SL, Weinberg AD, English M, Huston G. IL-4 
directs the development of Th2-like helper effectors. J 
Immunol 1990; 145: 3796-3806. 
21. Lee BJ, Moon HG, Shin TS, Jeon SG, Lee EY, Gho YS, 
Lee CG, Zhu Z, Elias JA, Kim YK. Protective effects of 
basic fibroblast growth factor in the development of 
emphysema induced by interferon-γ. Exp Mol Med 
2011; 43: 169-178. 
22. Lin Y, Zhou X, Guo W, Li Q, Pan X, Bao Y, He M, Zhu B, 
Lin X, Jin L. RhIL-11 treatment normalized Th1/Th2 and 
T-bet/GATA-3 imbalance in in human immune 
thrombocytopenic purpura (ITP). Int Immunopharmacol 
2016; 38: 40-44. 
23. Shin HS, See HJ, Jung SY, Choi DW, Kwon DA, Bae MJ, 
Sung KS, Shon DH. Turmeric (Curcuma longa) 
attenuates food allergy symptoms by regulating type 
1/type 2 helper T cells (Th1/Th2) balance in a mouse 
model of food allergy. J Ethnopharmacol 2015; 175: 21-
29.  
24. Duffy L, O'Reilly SC. Toll-like receptors in the 
pathogenesis of autoimmune diseases: recent and 
emerging translational developments. Immuno Target 
Ther 2016; 5: 69-80. 
25. Lei W, Browning JD Jr, Eichen PA, Lu CH, Mossine VV, 
Rottinghaus GE, Folk WR, Sun GY, Lubahn DB, 
Fritsche KL. Immuno-stimulatory activity of a 
polysaccharide-enriched fraction of Sutherlandia 
frutescens occurs by the toll-like receptor-4 signaling 
pathway. J Ethnopharmacol 2015; 172: 247-253.  
26. Achek A, Yesudhas D, Choi S. Toll-like receptors: 
promising therapeutic targets for inflammatory diseases. 
Arch Pharm Res 2016; 39: 1032-1049. 
27. Im EJ, Kim SJ, Hong SB, Park JK, Rhee MH. Anti-
Inflammatory Activity of Bee Venom in BV2 Microglial 
Cells: Mediation of MyD88-Dependent NF-κB Signaling 
Pathway. Evid Based Compl Alt Med 2016; 2016: 
3704764. 
28. Flaherty S, Reynolds JM. TLR Function in Murine CD4 
(+) T Lymphocytes and Their Role in Inflammation. 
Method Mol Biol 2016; 1390: 215-227. 
29. Walker JK, Fong AM, Lawson BL, Savov JD, Patel DD, 
Schwartz DA, Lefkowitz RJ. Beta-arrestin-2 regulates 
the development of allergic asthma.  J Clin Invest 2003; 
112: 566-574. 
 
